Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Drug Updates
Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
,
Drug Updates
,
Payers' Guide
Trends in the 2013 Pharmaceutical Pipeline
Dalia Buffery, MA, ABD
,
Atheer A. Kaddis, PharmD
Read More
FDA Approvals
,
Drug Updates
,
Payers' Guide
FDA Approvals of Brand-Name Prescription Drugs in 2012
Read More
FDA Approvals
,
Drug Updates
,
Payers' Guide
Foreword: The Fourth Annual Payers’ Guide to New FDA Approvals
Read More
FDA Approvals
,
Drug Updates
,
Payers' Guide
Introduction: New FDA Drug Approvals in 2012: A 15-Year High
Gary M. Owens, MD
Read More
Drug Updates
Ponatinib: New Option for the Treatment of Adults with CML or Ph+ ALL that Is Resistant or Intolerant to Previous Therapy with Tyrosine Kinase Inhibitors
Lynne Lederman, PhD
Read More
Drug Updates
Qsymia: Combination Oral Therapy a New Weight-Loss Option for Obese or Overweight Patients
... .. ...., ....
Read More
Drug Updates
Belviq: A New Prescription Weight-Loss Treatment for Overweight or Obese Patients
... .. ...., ....
Read More
Drug Updates
Payer Drug and Molecular Testing Utilization Policies
Charles Bankhead, Medical Writer
Read More
Clinical
,
Drug Updates
Strategies to Prevent Opioid Misuse, Abuse, and Diversion That May Also Reduce the Associated Costs
Kathryn L. Hahn, PharmD, DAAPM, CPE
Stakeholder Perspective
Just Say No
by
Atheer A. Kaddis, PharmD
Read More
5
6
7
8
Page 8 of 8
Results 71 - 80 of 80